Walleye Capital
TBIO

Walleye Capital’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Walleye Capital’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,383
Closed -$258K – 1031
2020
Q2 		$258K Buy
+14,383
New +$217K 0.06% 371

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Walleye Capital's TBIO Position: Q3 2020 in Review

Walleye Capital sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2020, closing a stake of 14,383 shares — an estimated $258K sold.

Walleye Capital first reported a position in TBIO in Q2 2020 and held it in 1 quarter. The position peaked at $258K in Q2 2020. 132 funds tracked by Wall St. Rank hold TBIO as of Q3 2020.

  • Walleye Capital reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Walleye Capital sold 14,383 Translate Bio, Inc. Common Stock shares in Q3 2020, an estimated $258K.
  • Walleye Capital first reported a position in Translate Bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Walleye Capital's Translate Bio, Inc. Common Stock position peaked at $258K in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2020.

Based on Walleye Capital's 13F filing for Q3 2020, filed 16 Nov 2020.